Immuno-combined treatment versus radio-combined treatment in limited-stage small-cell lung cancer
Background: Although the approval of immunotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) has significantly improved the patient’s prognosis, synchronous chemoradiotherapy has always been the standard treatment for limited-stage small-cell lung cancer (LS-SCLC). Objectives...
Saved in:
| Main Authors: | Li Tong, Xiaomi Li, Mingming Hu, Minghang Zhang, Yishuo Wang, Kai Zhang, Qunhui Wang, Tongmei Zhang, Baolan Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-12-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359241307191 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prognostic value of immuno-inflammatory biomarkers in esophageal squamous cell carcinoma patients receiving immunotherapy combined with chemoradiotherapy and its association with immuno-genomic landscape
by: Xingyuan Cheng, et al.
Published: (2024-12-01) -
Carboplatin combined with arsenic trioxide versus carboplatin combined with docetaxel treatment for LACC: A randomized, open-label, phase II clinical study
by: Li Sijin, et al.
Published: (2024-12-01) -
Promising first‐line immuno‐combination therapies for unresectable hepatocellular carcinoma: A cost‐effectiveness analysis
by: Feng Wen, et al.
Published: (2024-08-01) -
Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies
by: Yuzhu Chen, et al.
Published: (2025-01-01) -
Advanced treatment of giant proliferating trichilemmal tumor: Limited resection combined with neoadjuvant ALA-PDT
by: Caihe Liao, et al.
Published: (2024-02-01)